Founded in 2019, Grannus Therapeutics is a pre-clinical stage biotechnology company, focused on the development of small molecule inhibitors for specific isoforms of HSP90. Our lead program is focused on the development of a highly selective small molecule inhibitor of HSP90𝛽 for the treatment of multiple types of cancer. With this program, we have successfully engineered a molecule that selectively inhibits HSP90𝛽, potentially delivering the efficacy benefits of previous pan-inhibitors without their toxicity and dosing challenges.
Is this your company?
Something looks off?